ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics Second Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, August 6, 2025.
Adma Biologics Inc. (ADMA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Royce & Associates Chuck Royce | 639,249 | $11,640,724 | -9% | 0.12% |
| 2. | Aubrey Capital Management Andrew Dalrymple And Barry Mccorkell | 189,800 | $3,454,785 | 1.25% | |
| 3. | Navellier & Associates Louis Navellier | 169,960 | $3,094,972 | -1% | 0.38% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.71 | 130,000 | $482,144.00 | 443,265 | 2023-08-30 | Filing | |
| $3.90 | 25,000 | $97,500.00 | 277,401 | 2023-08-24 | Filing | |
| $2.86 | 6,993 | $19,999.98 | 1,034,825 | 2022-12-09 | Filing | |
| $2.86 | 14,982 | $42,848.52 | 1,143,426 | 2022-12-09 | Filing | |
| $2.86 | 14,983 | $42,851.38 | 2,203,708 | 2022-12-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.66 | 6,000 | $111,960.00 | 2,037,850 | 2025-07-15 | Filing | |
| $18.66 | 15,000 | $279,900.00 | 2,043,850 | 2025-07-15 | Filing | |
| $20.81 | 6,000 | $124,860.00 | 2,043,850 | 2025-06-16 | Filing | |
| $20.81 | 15,000 | $312,150.00 | 2,049,850 | 2025-06-16 | Filing | |
| $20.24 | 194,749 | $3,941,719.76 | 87,330 | 2025-06-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,913,121 | $107,690,516 | 0.01% | |
| 2. | 3,320,251 | $59,366,087 | 0.1% | |
| 3. | 2,894,286 | $52,704,948 | 0.62% | |
| 4. | 1,800,440 | $32,786,012 | 0.31% | |
| 5. | 1,546,435 | $28,160,580 | 0.01% |
News See All
Heavy Insider Selling at ADMA Biologics Despite Earnings Strength
Headquartered in New Jersey, ADMA Biologics, Inc. (NASDAQ:ADMA) is the only U.S.-based producer of plasma-derived immunoglobulin therapies.
13 Best Low Risk High Growth Stocks to Buy
The current market is witnessing political chess moves, which are also affecting policy changes.
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios
ADMA Biologics fell by 14.7 percent week-on-week, closing Friday at $17.74 versus the $20.81 on June 13, as investors took path from three of its executives’ recent disposition of shares in the company...
ADMA Biologics (ADMA) Drops for 5th Consecutive Day - Here's Why
While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
10 Best Multibagger Stocks to Buy According to Billionaires
US Trade tariffs have triggered heightened volatility and amplified the downdraft in the equity markets.
Louis Navellier's 10 New Stock Picks
Navellier & Associates is an independent money management firm founded in 1987 by renowned growth analyst Louis Navellier.
10 Jim Cramer Stocks to Watch This Month
"They wipe out these gains pretty easily, don't they? Just like that, the sellers take away months, if not years, of profits because they want to get ahead of a potential recession.
Billionaire Hedge Funds
